A share price of BioXcel Therapeutics Inc [BTAI] is currently trading at $2.02, up 0.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BTAI shares have gain 12.85% over the last week, with a monthly amount drifted -7.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioXcel Therapeutics Inc [NASDAQ: BTAI] stock has seen the most recent analyst activity on February 21, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $4 from $9. Previously, Mizuho downgraded its rating to Neutral on August 15, 2023, and dropped its price target to $4. On July 17, 2023, downgrade downgraded it’s rating to Neutral. Jefferies downgraded its rating to a Hold and increased its price target to $22 on March 10, 2023. Goldman upgraded its rating to a Neutral but $16 remained the price target by the analyst firm on December 01, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $19. In a note dated April 06, 2022, BofA Securities reiterated a Buy rating on this stock but restated the target price of $80.
BioXcel Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.17 and $8.08. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. BioXcel Therapeutics Inc [NASDAQ: BTAI] shares were valued at $2.02 at the most recent close of the market. An investor can expect a potential return of 494.06% based on the average BTAI price forecast.
Analyzing the BTAI fundamentals
Trailing Twelve Months sales for BioXcel Therapeutics Inc [NASDAQ:BTAI] were 0.75M which represents -54.21% decline. Gross Profit Margin for this corporation currently stands at -0.38% with Operating Profit Margin at -66.98%, Pretax Profit Margin comes in at -90.71%, and Net Profit Margin reading is -90.71%. To continue investigating profitability, this company’s Return on Assets is posted at -1.52, Equity is 0.72 and Total Capital is -7.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioXcel Therapeutics Inc [NASDAQ:BTAI] is 1.17. As well, the Quick Ratio is 1.16, while the Cash Ratio is 0.99. Considering the valuation of this stock, the price to sales ratio is 58.90.
